title: Activation of checkpoint kinase 2 by 3,3'-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells.
abstract: We evaluated the effect of 3,3'-diindolylmethane (DIM) in ovarian cancer cells. DIM treatment inhibited the growth of SKOV-3, TOV-21G, and OVCAR-3 ovarian cancer cells in both a dose- and time-dependent manner with effective concentrations ranging from 40 to 100 muM. Growth-inhibitory effects of DIM were mediated by cell cycle arrest in G(2)/M phase in all the three cell lines. G(2)/M arrest was associated with DNA damage as indicated by phosphorylation of H(2)A.X at Ser139 and activation of checkpoint kinase 2 (Chk2) in all the three cell lines. Other G(2)/M regulatory molecules such as Cdc25C, Cdk1, cyclin B1 were down-regulated by DIM. Cycloheximide or Chk2 inhibitor pretreatment abrogated not only activation of Chk2 but also G(2)/M arrest and apoptosis mediated by DIM. To further establish the involvement of Chk2 in DIM-mediated G(2)/M arrest, cells were transfected with dominant-negative Chk2 (DN-Chk2). Blocking Chk2 activation by DN-Chk2 completely protected cells from DIM-mediated G(2)/M arrest. These results were further confirmed in Chk2 knockout DT40 lymphoma cells, in which DIM failed to cause cell cycle arrest. These results clearly indicate the requirement of Chk2 activation to cause G(2)/M arrest by DIM in ovarian cancer cells. Moreover, blocking Chk2 activation also abrogates the apoptosis-inducing effects of DIM. Furthermore, our results show that DIM treatment cause ROS generation. Blocking ROS generation by N-acetyl cysteine protects the cells from DIM-mediated G(2)/M arrest and apoptosis. Our results establish Chk2 as a potent molecular target of DIM in ovarian cancer cells and provide the rationale for further clinical investigation of DIM.
authors.affiliation: Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.
authors.forename: Prabodh K
authors.initials: PK
authors.lastname: Kandala
authors.forename: Sanjay K
authors.initials: SK
authors.lastname: Srivastava
mesh_terms: D017209:Apoptosis; D002455:Cell Division; D045744:Cell Line, Tumor; D064447:Checkpoint Kinase 2; D004249:DNA Damage; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D005260:Female; D005434:Flow Cytometry; D016195:G2 Phase; D006801:Humans; D047468:Immunoprecipitation; D020287:In Situ Nick-End Labeling; D007211:Indoles / Q000494:pharmacology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D010766:Phosphorylation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism*
chemical_list: D007211:Indoles; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases; C016392:3,3'-diindolylmethane
references.citation: Cancer Prev Res (Phila). 2009 Jun;2(6):581-9
references.pmid: 19470789
references.citation: Gynecol Oncol. 1999 Feb;72(2):215-9
references.pmid: 10021304
references.citation: Free Radic Biol Med. 2008 May 15;44(10):1833-45
references.pmid: 18342637
references.citation: Cancer Res. 2001 Jul 1;61(13):4990-3
references.pmid: 11431331
references.citation: Carcinogenesis. 2005 Apr;26(4):771-8
references.pmid: 15661811
references.citation: J Biol Chem. 2004 Jun 11;279(24):25813-22
references.pmid: 15073169
references.citation: Mol Cell Biol. 2002 Sep;22(18):6521-32
references.pmid: 12192050
references.citation: J Nutr. 2006 Nov;136(11):2728-34
references.pmid: 17056792
references.citation: Apoptosis. 2008 Dec;13(12):1465-78
references.pmid: 19002586
references.citation: Mol Cancer Ther. 2002 Jun;1(8):639-49
references.pmid: 12479224
references.citation: Am J Pathol. 2004 May;164(5):1511-8
references.pmid: 15111296
references.citation: Chem Res Toxicol. 1992 Mar-Apr;5(2):188-93
references.pmid: 1643248
references.citation: Carcinogenesis. 2002 Aug;23(8):1297-305
references.pmid: 12151347
references.citation: Toxicol Appl Pharmacol. 2007 Jan 15;218(2):174-85
references.pmid: 17174997
references.citation: Oncogene. 2009 Mar 12;28(10):1366-78
references.pmid: 19151762
references.citation: Mol Biol Cell. 2004 Sep;15(9):3965-76
references.pmid: 15181148
references.citation: Br J Cancer. 2009 May 5;100(9):1425-33
references.pmid: 19401701
references.citation: Genes Dev. 2004 May 15;18(10):1144-53
references.pmid: 15131084
references.citation: Biochem Pharmacol. 2007 Feb 15;73(4):469-80
references.pmid: 17118344
references.citation: J Natl Cancer Inst. 2009 Feb 4;101(3):176-93
references.pmid: 19176463
references.citation: Oncogene. 2008 Feb 7;27(7):896-906
references.pmid: 17684483
references.citation: Nature. 1997 Apr 24;386(6627):761, 763
references.pmid: 9126728
references.citation: Gynecol Oncol. 2002 Jul;86(1):85-90
references.pmid: 12079305
references.citation: Science. 1998 Nov 20;282(5393):1497-501
references.pmid: 9822382
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1708-19
references.pmid: 18566242
references.citation: EMBO J. 1999 Mar 1;18(5):1223-34
references.pmid: 10064589
references.citation: Cancer Lett. 2005 Dec 18;230(2):260-70
references.pmid: 16297712
references.citation: PLoS Genet. 2010 Feb 26;6(2):e1000863
references.pmid: 20195506
references.citation: Cancer Res. 2007 Apr 1;67(7):3310-9
references.pmid: 17409440
references.citation: Br J Cancer. 2002 Mar 4;86(5):712-7
references.pmid: 11875731
references.citation: Cell Prolif. 2000 Oct;33(5):261-74
references.pmid: 11063129
references.citation: Nature. 2000 Nov 23;408(6811):433-9
references.pmid: 11100718
references.citation: Cancer Res. 2006 May 1;66(9):4880-7
references.pmid: 16651444
references.citation: Cancer Res. 2006 May 1;66(9):4952-60
references.pmid: 16651453
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Biochem Pharmacol. 2002 Mar 15;63(6):1085-97
references.pmid: 11931841
references.citation: Int J Cancer. 2001 Sep;93(6):911-5
references.pmid: 11519057
references.citation: Am J Pathol. 2006 Nov;169(5):1833-42
references.pmid: 17071604
references.citation: Oncogene. 2004 Apr 12;23(16):2797-808
references.pmid: 15077143
references.citation: EMBO J. 2004 Jul 7;23(13):2554-63
references.pmid: 15192702
references.citation: DNA Repair (Amst). 2004 Aug-Sep;3(8-9):889-900
references.pmid: 15279774
references.citation: Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1521-7
references.pmid: 15342455
references.citation: EMBO J. 2002 Oct 1;21(19):5195-205
references.pmid: 12356735
references.citation: J Biol Chem. 2008 Jul 11;283(28):19322-8
references.pmid: 18480045
references.citation: Carcinogenesis. 2009 Oct;30(10):1744-53
references.pmid: 19549704